Information for companies wishing to market medicines imported via compassionate use, named patient
Published:
Changes
The Norwegian Medical Products Agency (NOMA) aims to facilitate a swift transition from unregistered to marketed medicines when companies choose to market medicines that are currently imported via compassionate use, named patient.
A rapid and smooth transition requires close cooperation between NOMA, major pharmacy wholesalers, and potentially healthcare institutions.
We therefore recommend that companies planning to market medicines currently imported via compassionate use, named patient, contact the wholesalers and the "Compassionate Use Team" as early as possible (godkjenningsfritak@dmp.no).